All News

The EdgeFlow UH10 bladder scanner utilizes high-resolution ultrasound imaging to non-invasively measure postvoid residual urine in the bladder.

According to Axonics, commercial sales of the R20 system in Europe are expected to begin in mid-April.

Overall, the phase 1/2 trial is designed to explore the safety, tolerability, pharmacokinetics, and preliminary clinical activity of NUV-1511 in patients with advanced solid tumors.

"I am still struggling with disposing the scopes after each use, both from the environmental aspect and the fact that the scope technically can be used more than once," writes Gopal H. Badlani, MD.

"The combination of highly potent systemic therapy and targeted radiation has shown impressive results in maintaining low PSA levels after testosterone recovery, offering hope for improved outcomes in these patients, but further studies are still needed to determine the best regimen," says Amar U. Kishan, MD.

Among all patients treated in the study to date, 60% demonstrated a PSA reduction of greater than 35%, and 27% demonstrated a PSA reduction of greater than 80%.

The therapy, known as Autologous Muscle Derived Cells for Urinary Sphincter Repair (iltamiocel), involves a medical procedure in which a participant’s own muscle cells are collected, processed, and then injected into the tissues of the urinary passage.

The VISTA-101 study has dosed all patients at dose level 5 of 6 in the KVA12123 monotherapy arm and all patients at the dose level 2 of 4 in the KVA12123-pembrolizumab combination arm.

The application for UGN-102 for low-grade intermediate-risk non–muscle-invasive bladder cancer is based on findings from the phase 3 ENVISION trial.

The odds of SUI recurrence following MUS were 17% to 24% among patients with childbirth vs 15% to 22% among patients without childbirth

The study is assessing RECCE 327 across the infusion times of 15, 20, 30, 45, and 60 minutes at the dose level of 3000 mg.

“Remarkably, relugolix demonstrated a faster return to baseline testosterone levels compared [with] traditional therapies, a crucial aspect for patients' quality of life post-treatment," says Daniel E. Spratt, MD.

Interest in AI in prostate cancer pathology has picked up speed since initial attempts of computer-aided diagnosis of the disease more than a decade ago, according to Peter A. Humphrey, MD, PhD.

"[Telemedicine] really has demonstrated itself to be a tool that can be used in a variety of ways, according to the discretion and ingenuity of the urologist," says Aaron Spitz, MD.

“This research suggests that proactive and continuous management of metabolic syndrome may serve as an essential strategy in preventing cancer," says Han-Ping Shi, MD, PhD.

The AACU is excited to announce its March 19, 2024 8PM EST webinar with Congressman Murphy.

"Now, physicians in Canada have a once-daily oral GnRH antagonist treatment option in their armamentarium that helps men with advanced prostate cancer by lowering testosterone levels without leading to testosterone flares,” said Fred Saad, MD, FRCS.

Artus is an artificial urinary sphincter for the treatment of patients with moderate to severe urinary incontinence.

“The impact of precision medicine in prostate cancer has been significant over a relatively brief period,” says Leonard G. Gomella, MD, FACS.

"[Now that] we have entered the era of precision and personalized medicine, well-designed clinical trials are needed to address selected focused questions regarding optimal therapy sequencing,” says Maha H.A. Hussain, MBChB.

Preliminary data showed that the treatment was well-tolerated, and a maximum tolerated dose had not yet been reached.

"From a usage perspective, it's going to be very easy for urologists or even for labs to transition from urine cytology over to using Oncuria because it's the same practice," says Dave Mori.

"Our outcomes showed 71% of patients achieved dry or near dry results in 6 to 12 weeks," says Nissrine Nakib, MD.

In this interview, Joshua Langston, MD, highlights a session on Medicare reimbursement reform from the 7th Annual AUA Urology Advocacy Summit.

The therapy is currently being manufactured in Italy at Curium facilities in Milan.

"Full discussion of the various fertility preservation options and an understanding of the fertility implications of the various treatment modalities must be understood by patients for them to make optimal decisions for their reproductive futures," write the authors.

"We are confident in PT-112's potential as an effective treatment for patients with mCRPC who have progressed on androgen receptor directed therapy, chemotherapy or radioligand therapy and who lack any effective immunotherapy," says Robert Fallon.

Overall, lesions less than 5 mm in size were detected across readers in 14% (7 of 50) of patients.

The approval is based on data from the phase 3 CheckMate-901 trial, which demonstrated improved overall survival and progression-free survival with the nivolumab-combination therapy vs cisplatin/gemcitabine alone.

Data showed that the combination of EV and pembrolizumab extended overall survival and progression-free survival vs chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma.